Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Proof of Concept Open-Label, Randomized, Controlled Study to Evaluate the Safety and Efficacy of MDI-1228-mesylate Gel Compared With Standard of Care Alone in Patients With Diabetic Foot Ulcers

NCT06852976 is registered in ClinicalTrials.gov with Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT06852976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06852976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Proof of Concept Open-Label, Randomized, Controlled Study to Evaluate the Safety and Efficacy of MDI-1228-mesylate Gel Compared With Standard of Care Alone in Patients With Diabetic Foot Ulcers
Lead sponsor
Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
March 12, 2025
Completion date
December 31, 2025
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic foot ulcer